ADVA Biotechnology and Cellipont Bioservices to Showcase Automated CAR-T Manufacturing Breakthrough at Advanced Therapies Week 2025

ADVA Biotechnology and Cellipont Bioservices announced their participation at Advanced Therapies Week 2025, where they will present a showcase study highlighting their successful collaboration in transitioning a CAR-T process from a complex manual workflow to a streamlined, automated solution. The study demonstrates enhanced process control and consistency through the implementation of the ADVA X3® Cell Manufacturing Platform, which integrates advanced in-process controls, artificial intelligence, and machine learning to simplify and accelerate CAR-T manufacturing.

The platform enables a fast and seamless transition from research and development to Good Manufacturing Practice (GMP) production while maintaining consistency, quality, and scalability. Key highlights of the showcase study include in-process controls with 14 parameters that provide precise monitoring and optimization, improving process consistency and reducing variability. The study also demonstrates how the ADVA X3 accelerates the transition from R&D to GMP, saving time and resources while ensuring robust process outcomes.

The comprehensive benefits of the ADVA X3® platform include cost efficiency by minimizing manual interventions and streamlining workflows, accelerated transition from R&D to GMP through 14 controlled parameters and online sensing, flexibility to support a wide range of cell therapies including CAR-T, TCR, NK, and TILs, AI and machine learning integration for predictive analytics and adaptive process adjustments, and an end-to-end solution that combines all required unit operations for a complete manufacturing process. For more information about ADVA Biotechnology, visit https://www.advabio.com.

Dr. Ohad Karnieli, Founder and CEO of ADVA Biotechnology, stated that the collaboration with Cellipont Bioservices, whose unique expertise in process development and GMP manufacturing is crucial in accelerating CAR-T production, demonstrates how the ADVA X3® platform can streamline the development and commercialization of cell therapies. Darren Head, CEO of Cellipont Bioservices, added that their efforts will improve the manufacturing of cell therapies by enhancing efficiency, reducing development time, and ensuring high-quality outcomes for patients. Additional details about Cellipont Bioservices can be found at https://www.cellipont.com.